Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

Journal of Clinical Oncology

Volumn 19, Issue 2, 2001, Pages 364-367

  Thigpen, T ^a   Brady, M F ^a   Homesley, H D ^a   Soper, J T ^a   Bell, J ^a  

^a Gynecol Oncol Grp Admin Office   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER HORMONE THERAPY; CANCER SURVIVAL; ENDOMETRIUM CARCINOMA; FEMALE; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT OUTCOME;

EID: 0035863402     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.2.364     Document Type: Article

References (13)

1. Cancer statistics, 1999
2. Advanced and recurrent endometrial carcinoma: Hormonal therapy
3. Chemotherapy of metastatic endometrial cancer
4. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group
5. Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma: Results of therapy and correlation with estrogen and progesterone receptor levels - The Gynecologic Oncology Group experience
6. Chemotherapy for advanced or recurrent gynecologic cancer
7. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: A Gynecologic Oncology Group study
8. Approximate is better than exact for the interval estimation of binomial proportions
9. Nonparametric estimation from incomplete observations
10. Asymptotically efficient rank invariant procedures
11. Progestin therapy of endometrial, breast, and ovarian carcinoma: A review of clinical observations
12. Hydroxyprogesterone caproate therapy in advanced endometrial cancer
13. Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to an antiestrogen